Snoretox has been recognised on the global stage, taking home the 2025 Innovation Award at the KC Animal Health Summit in Kansas City.
The award, one of the most prestigious in the global animal health sector, honours the most outstanding new pharmaceutical, device or practice-related intervention in veterinary care.
Snoretox was selected unanimously from a field of 41 applicants for its tetanus-based neuromuscular stimulatory drug targeting Brachycephalic Obstructive Airway Syndrome (BOAS). BOAS is a debilitating breathing disorder affecting more than 20 million dogs worldwide, particularly breeds such as British Bulldogs, French Bulldogs and Pugs.
The company’s patented therapeutic has already been granted breakthrough designation by the US Food and Drug Administration Center for Veterinary Medicine, further underscoring its potential to reshape the treatment landscape for BOAS.
This international recognition is expected to accelerate commercial opportunities and partnerships for Snoretox, reflecting growing global interest in innovative solutions that improve the quality of life for companion animals.